Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $18.75.
A number of research analysts recently weighed in on the stock. Weiss Ratings raised shares of Kalaris Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday.
View Our Latest Report on Kalaris Therapeutics
Kalaris Therapeutics Stock Down 7.3%
Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06. Sell-side analysts predict that Kalaris Therapeutics will post -1.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Kalaris Therapeutics
Hedge funds have recently modified their holdings of the company. Sigma Planning Corp purchased a new position in shares of Kalaris Therapeutics in the 2nd quarter worth approximately $41,000. Empowered Funds LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at approximately $65,000. WealthTrust Asset Management LLC bought a new position in shares of Kalaris Therapeutics in the first quarter valued at approximately $72,000. Velan Capital Investment Management LP grew its holdings in shares of Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock valued at $102,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Kalaris Therapeutics by 146.8% during the third quarter. Goldman Sachs Group Inc. now owns 39,616 shares of the company’s stock valued at $114,000 after acquiring an additional 23,562 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.
Kalaris Therapeutics Company Profile
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.
Recommended Stories
- Five stocks we like better than Kalaris Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
